

Prophylaxis of Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its review of prophylaxis of hereditary angioedema (HAE) with lanadelumab and C1 inhibitors. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories. None of these individuals or organizations are responsible for the final contents of ICER's report or should be assumed to support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- Academy of Managed Care Pharmacy
- Aetna, Inc.
- Anthem, Inc.
- American Academy of Allergy, Asthma, and Immunology (AAAAI)
- Blue Shield of California
- California Department of Health Care Services
- Cigna, Inc.
- CSL Behring
- Health Net, Inc.
- Kaiser Permanente
- National Organization for Rare Disorders (NORD)
- Pharming
- Premera Blue Cross
- Shire
- UnitedHealthcare Services, Inc.
- United States Hereditary Angioedema Association (US HAEA)